Christoph U. Correll, MD

Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.

Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.

Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.

Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.

Olanzapine-samidorphan keeps olanzapine efficacy yet limits weight gain, boosts negative symptoms, and cuts ER visits in real-world care.

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.

New data shared at ECNP Congress informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of Perseris to risperidone (Uzedy).

Check out these exciting updates from the recent RISE study on TV-46000, a subcutaneous long-acting injectable antipsychotic formulation of risperidone.

For the past 7 decades, there has only been 1 mechanism of action for schizophrenia treatment. Christoph Correll, MD, talks new options and cognitive impairment at the 2024 APA Annual Meeting.

Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.

Although psychotropic medications have revolutionized the treatment of many psychiatric disorders, the benefits sometimes come at a price.